

Received: from CEXMB002.nmes.lcl ([fe80::f050:e955:c6de:7bf0]) by
CEXHUB003.nmes.lcl ([::1]) with mapi id 14.03.0224.002; Fri, 22 May 2015
09:47:09 -0600
From: "Swatek, Joshua, DOH" <Joshua.Swatek@state.nm.us>
To: "Kesner, Ben., RLD" <Ben.Kesner@state.nm.us>, "Heinz Bennett, Melissa,
DOH" <Melissa.Heinz-Bennett@state.nm.us>
Subject: RE: Naloxone
Thread-Topic: Naloxone
Thread-Index: AdCRphXUkQXJa71yRMGrPSrHt5RzsQCW9kHQACfuCZAAQ4dIA==
Date: Fri, 22 May 2015 15:47:08 +0000
Message-ID: <9520AA9D8760DD499C4A5F25505B795219A97A@CEXMB002.nmes.lcl>
References: <B6049650E7BD8D44A97BBD23BBC9E5452684F637@CEXMB003.nmes.lcl>
<9520AA9D8760DD499C4A5F25505B795219A150@CEXMB002.nmes.lcl>
<B6049650E7BD8D44A97BBD23BBC9E545268518DA@CEXMB003.nmes.lcl>
In-Reply-To: <B6049650E7BD8D44A97BBD23BBC9E545268518DA@CEXMB003.nmes.lcl>
Accept-Language: en-US
Content-Language: en-US
X-MS-Exchange-Organization-AuthMechanism: 04
X-MS-Exchange-Organization-AuthSource: CEXHUB003.nmes.lcl
X-MS-Has-Attach:
X-MS-Exchange-Organization-SCL: -1
X-MS-TNEF-Correlator:
Content-Type: multipart/alternative;
boundary="____000_9520AA9D8760DD499C4A5F25505B795219A97ACEXMB002nmeslcl_"
MIME-Version: 1.0

--____000_9520AA9D8760DD499C4A5F25505B795219A97ACEXMB002nmeslcl_
Content-Type: text/plain; charset="us-ascii"
Content-Transfer-Encoding: quoted-printable

Good Morning,

Thanks Ben, the wording on that is really 6 one way half a dozen the other.=
I was trying to make it so regulations don't have to be changed in case an=other product is introduced to the market and to match current language in =our statutes and regs. I will certainly do my best to make the hearing in J=une and in August or October. I hope you have a fantastic long weekend!

Josh

From: Kesner, Ben., RLD
Sent: Friday, May 22, 2015 9:18 AM
To: Swatek, Joshua, DOH; Heinz Bennett, Melissa, DOH
Subject: RE: Naloxone

Hello,

I made some of your changes. The revision is attached. If you can get the=NMMB to say Opioid Antagonist, I will change it. Remember, this presentat=

ion at the June NMBOP meeting is only to request this to be noticed for hearing. But if you are available, you can make any suggestions you want then. The actual hearing will be in August or October. It might not be August because this meeting will be in Ruidoso. And people will have a harder time getting to Ruidoso. When the hearing is held, you will know, and I hope you are there.

Thank you, Ben

Ben Kesner

Executive Director

Regulation and Licensing Department

New Mexico Board of Pharmacy

(505) 222-9838 - Office

(505) 222-9845 - Fax

ben.kesner@state.nm.us<mailto:ben.kesner@state.nm.us>

www.rld.state.nm.us/pharmacy<http://www.rld.state.nm.us/pharmacy>

REPORT CHILD ABUSE OR NEGLECT # SAFE (#7233) from a cell phone or 1-855-33=3-SAFE .

Confidentiality Notice: This e-mail, including all attachments is for the sole use of the intended recipient[s] and may contain confidential and/or privileged information. Any unauthorized use, copying, disclosure or distribution is prohibited, unless specifically provided under New Mexico Inspection of Public Records Act. If you are not the intended recipient, please contact the sender at once and destroy all copies of this message.

From: Swatek, Joshua, DOH
Sent: Thursday, May 21, 2015 2:17 PM
To: Kesner, Ben., RLD; Heinz Bennett, Melissa, DOH
Subject: RE: Naloxone

Good Afternoon,

Sorry it has taken me some time to get back with you on this, I've been out of the office due to a family emergency and just got the chance to take a look at it. A lot of it looks very similar to what I had down and didn't ge=

t the chance to send out due my time out of the office. I did make a few minor changes to the naloxone section, I'm not comfortable enough with school-based regulations to make changes on that, primarily I simplified the definition of a CBO licensed facility, and moved the limitations of ownership into the CBO section itself. I also removed the NM board standing order portion. To the best of my understanding there is not a standing order needed for the administration of naloxone as there is a statute and regulation that already provides for that with 24-23-1 NMSA 1978 and NMAC 7.32.7. I also removed mention of naloxone and replaced it with opioid antagonist, again this would allow for another potential antagonist to be used if one became available and would not force a regulation change. I hope this all makes sense and thank you so much for working on this Ben. If there are any questions please feel free to let me know and I will be more than happy to answer them for you. I hope you have a great day and again I apologize for the delay.

Thank you,

Josh

From: Kesner, Ben., RLD
Sent: Monday, May 18, 2015 2:08 PM
To: Heinz Bennett, Melissa, DOH; Swatek, Joshua, DOH
Subject: Naloxone

Hello,

Attached are my proposed regulation changes.

It contains more than adding Naloxone.

Please review the Naloxone sections.

Let me know if you have any suggestions, questions or comments.

Thank you, Ben

Ben Kesner
Executive Director
Regulation and Licensing Department
New Mexico Board of Pharmacy
(505) 222-9838 - Office

(505) 222-9845 - Fax

ben.kesner@state.nm.us<mailto:ben.kesner@state.nm.us>

www.rld.state.nm.us/pharmacy<http://www.rld.state.nm.us/pharmacy>

REPORT CHILD ABUSE OR NEGLECT # SAFE (#7233) from a cell phone or 1-855-33=3-SAFE .

Confidentiality Notice: This e-mail, including all attachments is for the sole use of the intended recipient[s] and may contain confidential and/or privileged information. Any unauthorized use, copying, disclosure or distribution is prohibited, unless specifically provided under New Mexico Inspection of Public Records Act. If you are not the intended recipient, please contact the sender at once and destroy all copies of this message.

--_000_9520AA9D8760DD499C4A5F25505B795219A97ACEXMB002nmeslcl_

Content-Type: text/html; charset="us-ascii"

Content-Transfer-Encoding: quoted-printable

```
<html xmlns:v=3D"urn:schemas-microsoft-com:vml" xmlns:o=3D"urn:schemas-microsoft-com:office:office" xmlns:w=3D"urn:schemas-microsoft-com:office:word" = xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml" xmlns=3D"http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3Dus-ascii"= >
<meta name=3D"Generator" content=3D"Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
    {font-family:"Cambria Math";
    panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
    {font-family:Calibri;
    panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
    {font-family:Tahoma;
    panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
    {margin:0in;
    margin-bottom:.0001pt;
    font-size:11.0pt;
    font-family:"Calibri", sans-serif;}
a:link, span.MsoHyperlink
    {mso-style-priority:99;
    color:blue;
    text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
    {mso-style-priority:99;
    color:purple;}
```

```
text-decoration:underline;}
```

p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
{mso-style-priority:99;
mso-style-link:"Balloon Text Char";
margin:0in;
margin-bottom:.0001pt;
font-size:8.0pt;
font-family:"Tahoma",sans-serif;}

span.BalloonTextChar
{mso-style-name:"Balloon Text Char";
mso-style-priority:99;
mso-style-link:"Balloon Text";
font-family:"Tahoma",sans-serif;}

span.EmailStyle19
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:windowtext;}

span.EmailStyle20
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}

span.EmailStyle21
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}

span.EmailStyle22
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}

.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}

@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}

div.WordSection1
{page:WordSection1;}

--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext=3D"edit" spidmax=3D"1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext=3D"edit">
<o:idmap v:ext=3D"edit" data=3D"1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang=3D"EN-US" link=3D"blue" vlink=3D"purple">
<div class=3D"WordSection1">
<p class=3D"MsoNormal">Good Morning,<o:p></o:=
p></p>
<p class=3D"MsoNormal"><o:p> </o:p></spa=
n></p>
<p class=3D"MsoNormal">Thanks Ben, the wordin=
g on that is really 6 one way half a dozen the other. I was trying to make =
it so regulations don’t have to be changed in case another product is=
introduced to the market and to match current
language in our statutes and regs. I will certainly do my best to make thee=
hearing in June and in August or October. I hope you have a fantastic long=
weekend!<o:p></o:p></p>
<p class=3D"MsoNormal"><o:p> </o:p></spa=
n></p>

<p class=3D"Ms0Normal">Josh <o:p></o:p></p>

<p class=3D"Ms0Normal"><o:p> </o:p></p>

<div>

<div style=3D"border:none; border-top:solid #E1E1E1 1.0pt; padding:3.0pt 0in = 0in 0in">

<p class=3D"Ms0Normal">From: Kesner, Ben., RLD

Sent: Friday, May 22, 2015 9:18 AM

To: Swatek, Joshua, DOH; Heinz Bennett, Melissa, DOH

Subject: RE: Naloxone<o:p></o:p></p>

</div>

</div>

<p class=3D"Ms0Normal"><o:p> </o:p></p>

<p class=3D"Ms0Normal">Hello,<o:p></o:p></p>

<p class=3D"Ms0Normal"><o:p> </o:p></p>

<p class=3D"Ms0Normal">I made some of your changes. The revision is attached. If you can get the NMMB to say= Opioid Antagonist, I will change it. Remember, this presentation at = the June NMBOP meeting is only to request this to be noticed for hearing. But if you are available, you can make any sugg= estions you want then. The actual hearing will be in August or Octobe= r. It might not be August because this meeting will be in Ruidoso.&nbs= p; And people will have a harder time getting to Ruidoso.

When the hearing is held, you will know, and I hope you are there.<o:p></o= :p></p>

<p class=3D"Ms0Normal"><o:p> </o:p></p>

<p class=3D"Ms0Normal">Thank you, Ben<o:p></o= :p></p>

<p class=3D"Ms0Normal"><o:p> </o:p></p>

<div>

<p class=3D"Ms0Normal">Ben Kesner<o:p></o:p><= /span></p>

<p class=3D"Ms0Normal">Executive Director<o:p= ></o:p></p>

<p class=3D"Ms0Normal">Regulation and Licensi= ng Department<o:p></o:p></p>

<p class=3D"Ms0Normal">New Mexico Board of Ph= armacy<o:p></o:p></p>

<p class=3D"Ms0Normal">(505) 222-9838 - Offic= e<o:p></o:p></p>

<p class=3D"Ms0Normal">(505) 222-9845 - Fax<o= :p></o:p></p>

<p class=3D"Ms0Normal">ben.kesner@state.nm.us<o:p></o:p></p>

<p class=3D"Ms0Normal">www.rld.state.nm.us/pharmacy<o:p></o:p></p>

<p class=3D"Ms0Normal"><o:p> </o:p></p>

<p class=3D"Ms0Normal">REPOR= T CHILD ABUSE OR NEGLECT

SAFE (#7233) from a cell phone or 1-855-333-SAFE .<= /span><o:p></o:p></p>

<p class=3D"Ms0Normal"><o:p>&nbsp</o:p></p>

<p class=3D"Ms0Normal">Confidentiality Notice:&nbsp This e-mail, including all attachments is for the sole use of the intended recipient[s] and may contain confidential and/or privileged information.&nbsp Any unauthorized use, copying, disclosure or distribution is prohibited, unless specifically provided under New Mexico Inspection of Public Records Act.&nbsp

If you are not the intended recipient, please contact the sender at once and destroy all copies of this message.=<o:p></o:p></p>

</div>

<p class=3D"Ms0Normal"><o:p>&nbsp</o:p></p>

<div>

<div style=3D"border:none; border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0in = 0in 0in">

<p class=3D"Ms0Normal">From: Swatek, Joshua, DOH

Sent: Thursday, May 21, 2015 2:17 PM

To: Kesner, Ben., RLD; Heinz Bennett, Melissa, DOH

Subject: RE: Naloxone<o:p></o:p></p>

</div>

</div>

<p class=3D"Ms0Normal"><o:p>&nbsp</o:p></p>

<p class=3D"Ms0Normal">Good Afternoon,<o:p></o:p></p>

<p class=3D"Ms0Normal"><o:p>&nbsp</o:p></p>

<p class=3D"Ms0Normal">Sorry it has taken me some time to get back with you on this, I've been out of the office due to a family emergency and just got the chance to take a look at it. A lot of it looks very similar to what I had down and didn't get the chance to send out due my time out of the office. I did make a few minor changes to the naloxone section, I'm not comfortable enough with school based regulations to make changes on that, primarily I simplified the definition of a CBO licensed facility, and moved the limitations of ownership into the CBO section itself. I also removed the NM board standing order portion. To the best of my understanding there is not a standing order needed for the administration of naloxone as there is a statute and regulation that already provides for that with 24-23-1 NMSA 1978 and NMAC 7.32.7. I also removed mention of naloxone and replaced it with opioid antagonist, again this would allow for another potential antagonist to be used if one became available and would not force a regulation change. I hope this all makes sense and thank you so much for working on this Ben. If there are any questions please feel free to let me know and I will be more than happy to answer them for you. I hope you have a great day and again I apologize for the delay.<o:p></o:p></p>

<p class=3D"Ms0Normal"><o:p>&nbsp</o:p></p>

<p class=3D"Ms0Normal">Thank you,<o:p></o:p></p>

<p class=3D"Ms0Normal">Josh <o:p></o:p>

></p>

<p class=3D"Normal"><o:p>&nbsp</o:p></p>

<div>

<div style=3D"border:none; border-top:solid #E1E1E1 1.0pt; padding:3.0pt 0in = 0in 0in">

<p class=3D"Normal">From: Kesner, Ben., RLD

Sent: Monday, May 18, 2015 2:08 PM

To: Heinz Bennett, Melissa, DOH; Swatek, Joshua, DOH

Subject: Naloxone<o:p></o:p></p>

</div>

</div>

<p class=3D"Normal"><o:p>&nbsp</o:p></p>

<p class=3D"Normal">Hello,<o:p></o:p></p>

<p class=3D"Normal"><o:p>&nbsp</o:p></p>

<p class=3D"Normal">Attached are my proposed regulation changes.<o:p></o:p></p>

<p class=3D"Normal">It contains more than adding Naloxone.<o:p></o:p></p>

<p class=3D"Normal">Please review the Naloxone sections.<o:p></o:p></p>

<p class=3D"Normal">Let me know if you have any suggestions, questions or comments.<o:p></o:p></p>

<p class=3D"Normal"><o:p>&nbsp</o:p></p>

<p class=3D"Normal">Thank you, Ben<o:p></o:p></p>

<p class=3D"Normal"><o:p>&nbsp</o:p></p>

<p class=3D"Normal">Ben Kesner<o:p></o:p></p>

<p class=3D"Normal">Executive Director<o:p></o:p></p>

<p class=3D"Normal">Regulation and Licensing Department<o:p></o:p></p>

<p class=3D"Normal">New Mexico Board of Pharmacy<o:p></o:p></p>

<p class=3D"Normal">(505) 222-9838 - Office<o:p></o:p></p>

<p class=3D"Normal">(505) 222-9845 - Fax<o:p></o:p></p>

<p class=3D"Normal">ben.kesner@state.nm.us<o:p></o:p></p>

<p class=3D"Normal">www.rld.state.nm.us/pharmacy<o:p></o:p></p>

<p class=3D"Normal"><o:p>&nbsp</o:p></p>

<p class=3D"Normal">REPORT CHILD ABUSE OR NEGLECT

SAFE (#7233) from a cell phone or 1-855-333-SAFE .<o:p></o:p></p>

<p class=3D"Normal"><o:p>&nbsp</o:p></p>

<p class=3D"Normal">Confidentiality Notice:&nbsp This e-mail, including all attachments is for the sole use of the intended recipient[s] and may contain confidential and/or privileged information.&nbsp Any unauthorized use, copying, disclosure or distribution is prohibited, unless specifically provided under New Mexico Inspection of Public Records Act.&nbsp

If you are not the intended recipient, please contact the sender at once and destroy all copies of this message.=<o:p></o:p></p><p class=3D"Ms0Normal"><o:p> </o:p></p></div></body></html>

--_000_9520AA9D8760DD499C4A5F25505B795219A97ACEXMB002nmeslcl_--